Alberta Physician Learning Program, University of Calgary, Calgary, AB, Canada.
Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
Clin Drug Investig. 2018 May;38(5):449-455. doi: 10.1007/s40261-018-0626-4.
Antipsychotic medication use has steadily increased in Canada, with an expansion in the profile of users and the diagnoses for which they are used. The use of antipsychotics is associated with a number of adverse effects for which routine monitoring is recommended. The objectives of this study were to determine the most common diagnoses associated with antipsychotic use in children in Alberta, Canada and the proportion who receive recommended laboratory tests for adverse effects.
Data on dispensed antipsychotics, diagnoses, prescribers, and laboratory testing were obtained from provincial data sources. To assess the frequency of metabolic and hormonal laboratory baseline and/or follow-up testing, the sample was divided into an antipsychotic-naïve cohort and an antipsychotic non-naïve cohort.
In 2014, 6916 children were dispensed at least one second- or third-generation antipsychotic. The most frequently dispensed antipsychotics were risperidone (3908 children), quetiapine (2140 children), and aripiprazole (1302 children). The majority of children prescribed risperidone were diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) or conduct disorder. Quetiapine was mainly prescribed for neurotic disorder or depression, while aripiprazole was prescribed most frequently for conduct disorder or neurotic disorders. Among antipsychotic-naïve patients, 17% had at least one laboratory test done at baseline, and 35% had at least one laboratory test done at follow-up. In the non-naïve patients, 42% had at least one follow-up laboratory test. Lipid and glucose testing were done in less than 5% of the naïve cohort at baseline, and in less than 15% at follow-up. In the non-naïve cohort, less than 22% received lipid or glucose testing during the year 2014.
The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. The vast majority of children prescribed antipsychotic medications do not undergo recommended laboratory tests.
抗精神病药物在加拿大的使用稳步增加,使用者的人群和使用诊断也在不断扩大。抗精神病药物的使用与许多不良反应相关,建议对此进行常规监测。本研究的目的是确定在加拿大艾伯塔省,与儿童抗精神病药物使用相关的最常见诊断以及接受不良反应推荐实验室检测的比例。
从省级数据来源获取抗精神病药物、诊断、处方者和实验室检测的数据。为了评估代谢和激素实验室基线和/或随访检测的频率,将样本分为抗精神病药物初治队列和非初治队列。
2014 年,有 6916 名儿童至少开了一种第二代或第三代抗精神病药物。最常开的抗精神病药物是利培酮(3908 名儿童)、喹硫平(2140 名儿童)和阿立哌唑(1302 名儿童)。开利培酮的大多数儿童被诊断为注意力缺陷多动障碍(ADHD)或品行障碍。喹硫平主要用于治疗神经症或抑郁症,而阿立哌唑则主要用于治疗品行障碍或神经症。在抗精神病药物初治患者中,17%的患者至少进行了一次基线实验室检测,35%的患者至少进行了一次随访实验室检测。在非初治患者中,42%的患者至少进行了一次随访实验室检测。在初治患者中,不到 5%的患者在基线时进行了血脂和血糖检测,不到 15%的患者在随访时进行了血脂和血糖检测。在非初治患者中,不到 22%的患者在 2014 年接受了血脂或血糖检测。
艾伯塔省儿童抗精神病药物的使用大部分是超适应证的,与破坏性行为障碍、抑郁症和焦虑症有关。绝大多数开抗精神病药物的儿童未接受推荐的实验室检测。